Lv7
4980 积分 2022-08-11 加入
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
4天前
已完结
PERSONALIZED MEDICINE IN ORAL CANCER
4天前
已完结
PDX models for functional precision oncology and discovery science
5天前
已完结
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
1个月前
已完结
[Introduction to the 9
1个月前
已完结
41 (PB029): Preclinical characterization of ABSK131, a potential best-in-class MTAcooperative PRMT5 inhibitor
3个月前
已关闭
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers
3个月前
已完结
Medicinal chemistry strategies targeting PRMT5 for cancer therapy
3个月前
已完结
503LBA LBA Orals: Results from CA240-0007, a phase 1/2 multiple expansion cohort study of BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del)
3个月前
已完结
OA04.04 Sacituzumab Govitecan as Second-Line Treatment in Patients with Extensive Stage Small Cell Lung Cancer
4个月前
已关闭
皖公网安备34019202002308
